What is the Return on Assets (ROA) of CureVac this year?
The Return on Assets (ROA) of CureVac is -0.33 undefined this year.
CureVac ROA 2024
CureVac ROA
-0.33
Ticker
CVAC
ISIN
NL0015436031
WKN
A2P71U
In 2024, CureVac's return on assets (ROA) was -0.33, a 14.06% increase from the -0.29 ROA in the previous year.
CureVac Aktienanalyse
What does CureVac do?
CureVac NV is a German biotechnology company that was founded in 2000 by Ingmar Hoerr, who still leads the company today. The company is headquartered in Tübingen and has a branch in Frankfurt am Main. CureVac's goal is to develop and produce innovative therapies to combat diseases. The history of CureVac began with a focus on the development of RNA-based therapeutics. RNA is a molecule that plays a central role in protein production within the cell. By using RNA in therapeutic applications, the body's own processes can be utilized to fight diseases. CureVac has successfully developed a variety of RNA-based therapeutics in recent years, which are in various stages of clinical development. CureVac's business model is based on providing its technology platform to other companies. These companies can use the platform to develop their own RNA-based therapeutics. CureVac receives fees for this service and also receives a share of any revenues resulting from these projects. CureVac also operates its own pipeline of therapeutic products based on various technologies. One important technology, for example, is the use of messenger RNA (mRNA) to produce proteins that can have a therapeutic effect. CureVac has entered into several partnerships with large pharmaceutical companies such as Sanofi and Boehringer Ingelheim to bring its products to market. The company benefits from the strength of its technology platform and its ability to develop new methods for the production of RNA-based therapeutics. Furthermore, CureVac has played an important role in containing the global COVID-19 pandemic. The company has developed an mRNA vaccine against the SARS-CoV-2 virus, which is approved in Europe. The vaccine has shown to be particularly effective and has a high efficacy against the various variants of the virus. CureVac has signed a contract with the European Union for the delivery of up to 405 million doses of its COVID-19 vaccine, making it an important partner in the fight against the pandemic. Overall, CureVac is a company with a strong focus on RNA-based therapeutics. The company has successfully built a strong technology platform in recent years, enabling other companies to develop their own RNA-based therapeutics. At the same time, CureVac has built its own pipeline of products in various stages of clinical development. The company benefits from the strength of its technology platform and its ability to develop sustainable and effective solutions for various diseases. The success of CureVac, particularly its role in the fight against the COVID-19 pandemic, has shown that RNA technology will play an important role in the future of biotechnology. CureVac ist eines der beliebtesten Unternehmen auf Eulerpool.com.ROA Details
Understanding CureVac's Return on Assets (ROA)
CureVac's Return on Assets (ROA) is a key performance indicator that measures the company's profitability in relation to its total assets. It is calculated by dividing the net income by the total assets. A higher ROA indicates efficient asset utilization to generate profits, reflecting managerial effectiveness and financial health.
Year-to-Year Comparison
Comparing CureVac's ROA year-over-year provides insights into the company’s operational efficiency and asset utilization trends. An increasing ROA demonstrates enhanced asset efficiency and profitability, while a declining ROA can indicate operational or financial challenges.
Impact on Investments
Investors consider CureVac's ROA as a crucial metric to evaluate the company’s profitability and efficiency. A higher ROA signifies that the company is effectively utilizing its assets to generate profits, making it a potentially attractive investment.
Interpreting ROA Fluctuations
Variations in CureVac’s ROA can be attributed to changes in net income, asset purchases, or operational efficiencies. Analyzing these fluctuations assists in assessing the company's financial performance, management efficiency, and strategic financial positioning.
Frequently Asked Questions about CureVac stock
What was the ROA of CureVac compared to the previous year?
The ROA of CureVac has increased by 14.06% compared to the previous year.
What consequences do high ROA have for investors of CureVac?
A high ROA is advantageous for investors of CureVac, as it indicates that the company efficiently utilizes its assets and generates good profits.
What are the consequences of low ROA for investors in CureVac?
A low ROA can be unfavorable for investors of CureVac as it indicates that the company is inefficiently utilizing its assets and may potentially achieve lower profits.
How does an increase in the ROA of CureVac affect the company?
An increase in ROA of CureVac can be an indicator of improved efficiency in asset utilization and higher profitability.
How does a reduction in ROA of CureVac impact the company?
A reduction in the ROA of CureVac can be an indicator of lower asset efficiency and profitability.
What are some factors that can influence the ROA of CureVac?
Some factors that can influence the ROA of CureVac include revenue, operating costs, asset structure, and industry average.
Why is the ROA of CureVac important for investors?
The ROA of CureVac is important for investors as it is an indicator of the company's profitability and efficiency in utilizing assets. It provides investors with information on how well the company utilizes its resources to generate profits.
What strategic measures can CureVac take to improve ROA?
To improve ROA, CureVac can take measures such as cost savings, revenue growth, optimizing asset structure, and diversifying its business activities. It is important for the company to conduct a thorough review of its financial situation to determine the best strategic measures to improve ROA.
How much dividend does CureVac pay?
Over the past 12 months, CureVac paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, CureVac is expected to pay a dividend of 0 EUR.
What is the dividend yield of CureVac?
The current dividend yield of CureVac is .
When does CureVac pay dividends?
CureVac pays a quarterly dividend. This is distributed in the months of .
How secure is the dividend of CureVac?
CureVac paid dividends every year for the past 0 years.
What is the dividend of CureVac?
For the upcoming 12 months, dividends amounting to 0 EUR are expected. This corresponds to a dividend yield of 0 %.
In which sector is CureVac located?
CureVac is assigned to the 'Health' sector.
Wann musste ich die Aktien von CureVac kaufen, um die vorherige Dividende zu erhalten?
To receive the latest dividend of CureVac from 12/18/2024 amounting to 0 EUR, you needed to have the stock in your portfolio before the ex-date on 12/18/2024.
When did CureVac pay the last dividend?
The last dividend was paid out on 12/18/2024.
What was the dividend of CureVac in the year 2023?
In the year 2023, CureVac distributed 0 EUR as dividends.
In which currency does CureVac pay out the dividend?
The dividends of CureVac are distributed in EUR.
Stock savings plans offer an attractive way for investors to build wealth over the long term. One of the main advantages is the so-called cost-average effect: by regularly investing a fixed amount in stocks or stock funds, you automatically buy more shares when prices are low, and fewer when they are high. This can lead to a more favorable average price per share over time. In addition, stock savings plans allow small investors access to expensive stocks, as they can participate with small amounts. Regular investment also promotes a disciplined investment strategy and helps to avoid emotional decisions, such as impulsive buying or selling. Furthermore, investors benefit from the potential appreciation of the stocks as well as from dividend distributions, which can be reinvested, enhancing the compounding effect and thus the growth of the invested capital.
The CureVac stock can be added to a savings plan with the following providers: Scalable Capital
Andere Kennzahlen von CureVac
Our stock analysis for CureVac Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of CureVac Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.
